Egset Alice Viktoria, Holm Camilla, Larsen Stine Rosenkilde, Nielsen Susanne Holm, Bach Jacob, Helweg-Larsen Jens Peter, Larsen Louise Vølund, Wanscher Jens Højberg, Godballe Christian
Dan Med J. 2017 Feb;64(2).
Fine-needle aspiration biopsy (FNAB) is the cornerstone of thyroid nodule evaluation. In most cases, FNAB can discriminate between benign and malignant disease. In other cases, it is only indicative of malignancy and the results are considered "suspicious". In Denmark, thyroid FNAB results are categorised into six groups: "inadequate", "cystic", "inconclusive", "benign", "suspicious" and "malignant". The risk of malignancy in the Danish "suspicious" group is of interest for patients as well as doctors participating in the diagnosis and treatment. The Danish Thyroid Surgery Database (THYKIR) registers preoperative thyroid FNAB and final histology. The aim of this study was to assess the malignancy risk among patients with a suspicious thyroid FNAB according to the Danish criteria and to identify possible predictors of malignant histology.
A prospective cohort counting 483 patients with a "suspicious" thyroid FNAB who had been treated surgically in The Region of Southern Denmark in the 2001-2013 period was retrieved from the THYKIR database.
The risk of malignancy in the Danish thyroid FNAB "suspicious" group is 22%. Serum thyroid-stimulating hormone outside the normal range and vocal cord palsy may be patient-related predictors of malignancy.
Awaiting the introduction of reliable tools for preoperative evaluation, the current practice with histo-logical clarification of the "suspicious" thyroid FNAB seems justified.
none.
not relevant.
细针穿刺活检(FNAB)是甲状腺结节评估的基石。在大多数情况下,FNAB能够区分良性和恶性疾病。在其他情况下,它仅提示恶性可能性,结果被认为“可疑”。在丹麦,甲状腺FNAB结果分为六组:“不充分”、“囊性”、“不确定”、“良性”、“可疑”和“恶性”。丹麦“可疑”组的恶性风险对于参与诊断和治疗的患者及医生而言都备受关注。丹麦甲状腺手术数据库(THYKIR)记录术前甲状腺FNAB及最终组织学结果。本研究旨在根据丹麦标准评估甲状腺FNAB结果可疑患者的恶性风险,并确定恶性组织学的可能预测因素。
从THYKIR数据库中检索出2001年至2013年期间在丹麦南部地区接受手术治疗的483例甲状腺FNAB结果“可疑”的患者组成的前瞻性队列。
丹麦甲状腺FNAB“可疑”组的恶性风险为22%。血清促甲状腺激素超出正常范围及声带麻痹可能是与患者相关的恶性预测因素。
在等待引入可靠的术前评估工具期间,目前对甲状腺FNAB结果“可疑”进行组织学明确的做法似乎是合理的。
无。
不相关。